Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real‐life data. Issue 6 (12th September 2021)

• Record Type: Journal Article
• Authors: Gürbüz, Mustafa; Doğan, İzzet; Akkuş, Erman; Ermiş, Hande; Utkan, Güngör; Vatansever, Sezai; Taş, Faruk
• Is Part Of: Dermatologic therapy. Volume 34:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-12
• Subjects: adverse events -- basal cell carcinoma -- prognosis -- treatment -- vismodegib; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15122
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: The study aims to evaluate the vismodegib treatment in local advanced (laBCC) and metastatic (mBCC) basal cell carcinoma. The data of 29 patients were retrospectively reviewed. The clinical and histopathological features of the patients and adverse events of vismodegib were recorded. Overall survival (OS) and progression‐free survival (PFS) were evaluated with Kaplan–Meier analysis. The median follow‐up period was 17 months (range: 1.6–57.3), and the median age at diagnosis 73 years (range: 39–88). The most common disease location was head and neck (86.2%), and the most common non‐skin sites of disease were lymph nodes (13.8%), bone (13.8%), lung (6.9%), and brain (6.9%). Three (10.3%) patients had Gorlin's syndrome. The number of metastatic patients was 5 (17.2%). With vismodegib treatment, the complete response rate was 27.6%, partial response 55.2%, and stable response 10.3%. Treatment responses were most frequently seen within 2 months from the beginning of vismodegib. The median OS was 43.3 ± 9.0 months (25.6–61.1) for all patients. The median PFS in the laBCC was 15.7 ± 1.8 months (12.2–19.3), and 12.1 ± 4.6 months (2.9–21.2) in the mBCC. In the univariable analysis for the OS, only the treatment after the vismodegib was statistically significant, showing chemotherapy was better comparing to no treatment or surgery. The most common adverse events were fatigue‐58.6%, muscle spasms‐48.3%, alopecia‐13.8%, and weight loss‐13.8%. This real‐life data study shows that vismodegib treatment in locally advanced and metastatic BCC was well tolerated and effective.